MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomise...
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
About this item
Full title
Author / Creator
Ascierto, Paolo A, MD , Schadendorf, Dirk, Prof , Berking, Carola, Prof , Agarwala, Sanjiv S, Prof , van Herpen, Carla ML, MD , Queirolo, Paola, MD , Blank, Christian U, MD , Hauschild, Axel, Prof , Beck, J Thaddeus, MD , St-Pierre, Annie, PhD , Niazi, Faiz, MPharm , Wandel, Simon, PhD , Peters, Malte, MD , Zubel, Angela, MD and Dummer, Reinhard, Prof
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
SummaryBackgroundPatients with melanoma harbouring Val600 BRAF mutations benefit from treatment with BRAF inhibitors. However, no targeted treatments exist for patients with BRAF wild-type tumours, including those with NRAS mutations. We aimed to assess the use of MEK162, a small-molecule MEK1/2 inhibitor, in patients with NRAS-mutated or Val600 BR...
Alternative Titles
Full title
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Authors, Artists and Contributors
Author / Creator
Schadendorf, Dirk, Prof
Berking, Carola, Prof
Agarwala, Sanjiv S, Prof
van Herpen, Carla ML, MD
Queirolo, Paola, MD
Blank, Christian U, MD
Hauschild, Axel, Prof
Beck, J Thaddeus, MD
St-Pierre, Annie, PhD
Niazi, Faiz, MPharm
Wandel, Simon, PhD
Peters, Malte, MD
Zubel, Angela, MD
Dummer, Reinhard, Prof
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1751229422
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751229422
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(13)70024-X
